Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gilead Sciences
(NQ:
GILD
)
66.70
+0.11 (+0.17%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gilead Sciences
< Previous
1
2
...
30
31
32
33
34
35
36
37
38
...
47
48
Next >
Diabetic Kidney Disease Market to Witness Upsurge in Growth During the Forecast Period – DelveInsight | Key Players – Bayer, Reata Pharma, Novartis, Dimerix, Kyowa Kirin, Gilead, Orbsen, and Others
March 10, 2022
Continue reading "Diabetic Kidney Disease Market to Witness Upsurge in Growth During the Forecast Period – DelveInsight | Key Players – Bayer, Reata Pharma, Novartis, Dimerix, Kyowa Kirin, Gilead,...
Via
Get News
Crohn’s Disease Market is Predicted to Exhibit Remarkable Growth by 2032, Analyzes DelveInsight | Key Companies – UCB, Abbvie, Genetech, Gilead, Celgene, Millennium Pharma, and Others
March 10, 2022
Continue reading "Crohn’s Disease Market is Predicted to Exhibit Remarkable Growth by 2032, Analyzes DelveInsight | Key Companies – UCB, Abbvie, Genetech, Gilead, Celgene, Millennium Pharma, and...
Via
Get News
Opinion: Building an Inclusive World Through Sports, Art, and Culture
March 10, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Topics
LGBTQ
Exposures
Diversity
Keto Benefits And Benefits of Drinking Ketones.
March 08, 2022
Via
Marketers Media
Congratulations to Taiyin Yang, EVP, for Being Elected to the 2022 Class of the National Academy of Engineering.
March 08, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Gilead Sciences' Trodelvy Study In Breast Cancer Meets Primary Endpoint
March 07, 2022
Gilead Sciences Inc (NASDAQ: GILD) announced results from the Phase 3 TROPiCS-02 study evaluating Trodelvy (sacituzumab govitecan-hziy) in patients with HR+/HER2- metastatic...
Via
Benzinga
How A Mixed Breast Cancer Study Cast Doubt On Gilead's Immunomedics Buyout
March 07, 2022
Gilead's Trodelvy had mixed test results in patients with breast cancer.
Via
Investor's Business Daily
Mark Dresser Elected First Openly-LGBTQ+ President of American Society for Clinical Pharmacology and Therapeutics
March 04, 2022
SOURCE: Gilead Sciences
Via
3BL Media
36 Stocks To Watch After Biden's First State of The Union Address
March 02, 2022
President Joe Biden hosted his first State of the Union Address Tuesday in front of members of Congress. In the speech, Biden discussed several items that he has already helped...
Via
Benzinga
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
March 06, 2022
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (...
Via
Benzinga
We're Proud to Have Supported a Special Issue of Tuskegee University's Journal of Healthcare, Science, and the Humanities
March 02, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Gilead Hit By FDA Complete Response Letter For Lenacapavir In HIV Infection
March 01, 2022
The FDA has issued a complete response letter (CRL) for Gilead Sciences Inc's (NASDAQ: GILD) application for lenacapavir for heavily treated multi-drug...
Via
Benzinga
Keto Vs Low Carb – Intermittent Fasting Vegan Diet For Weight Loss Site Relaunch
March 01, 2022
Via
Marketers Media
Where Gilead Sciences Stands With Analysts
February 28, 2022
Within the last quarter, Gilead Sciences (NASDAQ:GILD) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
February 28, 2022
On Monday morning, 66 companies achieved new lows for the year. Noteable 52-Week Lows: Gilead Sciences (NASDAQ:GILD) was the largest firm on a market cap basis to set a...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2022
February 28, 2022
Upgrades According to DA Davidson, the prior rating for Envestnet Inc (NYSE:ENV) was changed from Neutral to Buy. In the fourth quarter, Envestnet showed an EPS of $0.50, compared...
Via
Benzinga
A Peek Into The Markets: US Stock Futures Tumble Following New Sanctions Against Russia
February 28, 2022
Pre-open movers U.S. stock futures traded lower in early pre-market trade after the Dow Jones surged more than 800 points in the previous session. Investors are awaiting earnings...
Via
Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the...
Via
Talk Markets
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...
Via
Benzinga
3 Moonshot Stocks Insiders Are Buying. What Do They Know?
February 25, 2022
Biotech stocks aren't a sure thing, but one good sign is insiders buying up shares. These three all offer that enticing feature.
Via
InvestorPlace
Gilead Launches Pharmaceutical Education Program to Increase Workplace Diversity (Black Enterprise)
February 24, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Is Moderna the Next Gilead or the Next Regeneron?
February 22, 2022
MRNA stock is seen purely as a Covid-19 play. Until Moderna can prove it's not a one-hit wonder, shares are likely to remain depressed.
Via
InvestorPlace
Understanding Hepatitis D: 4 Questions With Professor Maria Buti
February 22, 2022
SOURCE: Gilead Sciences
Via
3BL Media
"Prudent" Biotech Bets
February 20, 2022
Here, we review two recommended biotechnology stocks following the release of their latest earnings reports. Let's take a look.
Via
Talk Markets
See Why Did FDA Update Merck's COVID-19 Pill Emergency Use Authorization
February 18, 2022
The FDA has revised the Emergency Use Authorization (EUA) for Merck & Co Inc's (NYSE: MRK) COVID-19 pill molnupiravir, explaining that it should be...
Via
Benzinga
Charting a Career to Help Reduce Health Inequity: Porscha's Story
February 18, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Gilead's Lenacapavir Shows Sustained Efficacy In Pretreated HIV Patients
February 17, 2022
Gilead Sciences Inc (NASDAQ: GILD) announced new one-year results from the ongoing Phase 2/3 CAPELLA trial evaluating lenacapavir in heavily pretreated multi-drug...
Via
Benzinga
The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios
February 17, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel...
Via
Benzinga
New Clinical Data Support the Sustained Efficacy of Long-acting Lenacapavir, Gilead’s Investigational HIV-1 Capsid Inhibitor
February 16, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Hookipa Pharma Stock Surges On HIV Pact With Gilead
February 16, 2022
Hookipa Pharma Inc (NASDAQ: HOOK) amended and restated collaboration and license agreement with Gilead Sciences Inc (NASDAQ: GILD) for arenaviral...
Via
Benzinga
< Previous
1
2
...
30
31
32
33
34
35
36
37
38
...
47
48
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.